MedTrace Logo

Study of Single Doses of IV Aerucin in Healthy Adults

NCT02486770 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2015-12-30

No results posted yet for this study

Summary

This study will evaluate the safety profile and pharmacokinetic behavior of a single administration of Aerucin in healthy adults at three different dosages.

Conditions

  • Healthy

Interventions

BIOLOGICAL

Aerucin 2.0mg/kg

IV Aerucin 2.0 mg/kg over 1 hour

BIOLOGICAL

Aerucin 8.0mg/kg

IV Aerucin 8.0 mg/kg over 1 hour

BIOLOGICAL

Aerucin 20.0 mg/kg

IV Aerucin 20 mg/kg over 1 hour

Sponsors & Collaborators

  • Aridis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Mohammed Al-Ibrahim, MD · SNBL

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02486770 on ClinicalTrials.gov